EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSGMOG00000018680
Gene Symbol: ATP1B2B
3 Cross references
203 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSGMOG00000017791
Gene Symbol: ATP1B3A
3 Cross references
236 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSGMOG00000013747
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSGMOG00000033812
Gene Symbol: LOC115544364
2 Cross references
146 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSGMOG00000029862
Gene Symbol: BCL2
1 Cross references
176 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSGMOG00000028582
Gene Symbol: BCL2L1
2 Cross references
226 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSGMOG00000028878
Gene Symbol: BCL2L10
3 Cross references
128 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSGMOG00000004425
Gene Symbol: BCR
2 Cross references
205 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSGMOG00000011470
Gene Symbol: BTK
2 Cross references
204 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSGMOG00000033052
Gene Symbol: CXCR4
3 Cross references
131 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSGMOG00000007994
Gene Symbol: LOC115554653
2 Cross references
354 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSGMOG00000002861
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).